-
公开(公告)号：US20160090364A1
公开(公告)日：2016-03-31
申请号：US14962923
申请日：2015-12-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Yan Zou , Mimi L. Quan
IPC: C07D237/32 , C07D401/10 , C07D413/12 , C07D513/04 , C07D403/12 , C07D417/12 , C07D405/12 , C07D417/14 , C07D403/10 , C07D401/12
CPC classification number: C07D237/32 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D513/04 , G05B19/418 , G05B19/4189 , G05B2219/31033 , G05B2219/32278 , Y02P90/04 , Y02P90/28
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性的ROCK抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其治疗心血管，平滑肌，肿瘤学，神经病理学，自身免疫性，纤维化和/或炎症性疾病的方法。
-
公开(公告)号：US09926282B2
公开(公告)日：2018-03-27
申请号：US14759495
申请日：2014-01-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Yan Zou , Mimi L. Quan , Vladimir Ladziata
IPC: C07D237/32 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D513/04 , C07D405/10 , C07D217/24 , C07D413/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048
CPC classification number: C07D237/32 , C07D217/24 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
Patent Agency Ranking
公开(公告)号：US09221767B2
公开(公告)日：2015-12-29
申请号：US14157564
申请日：2014-01-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Yan Zou , Mimi L. Quan
IPC: A61K31/502 , C07D237/32 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D513/04 , C07D217/24 , C07D413/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048
CPC classification number: C07D237/32 , C07D217/24 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D513/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性的ROCK抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其治疗心血管，平滑肌，肿瘤学，神经病理学，自身免疫性，纤维化和/或炎症性疾病的方法。
-
公开(公告)号：US20150353505A1
公开(公告)日：2015-12-10
申请号：US14759495
申请日：2014-01-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Yan Zou , Miami L. Quan , Vladimir Ladziata
IPC: C07D237/32 , C07D401/10 , C07D413/10 , C07D405/10 , C07D417/10 , C07D487/04 , C07D513/04 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D403/10 , C07D417/14
CPC classification number: C07D237/32 , C07D217/24 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性的ROCK抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其治疗心血管，平滑肌，肿瘤学，神经病理学，自身免疫性，纤维化和/或炎症性疾病的方法。
-
公开(公告)号：US10385026B2
公开(公告)日：2019-08-20
申请号：US15890436
申请日：2018-02-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter W. Glunz , Yan Zou , Mimi L. Quan , Vladimir Ladziata
IPC: C07D237/32 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D513/04 , C07D405/10 , C07D217/24 , C07D413/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US20180162823A1
公开(公告)日：2018-06-14
申请号：US15890436
申请日：2018-02-07
Applicant: Bristol-Myers Squibb Company
Inventor： Peter W. Glunz , Yan Zou , Mimi L. Quan , Vladimir Ladziata
IPC: C07D237/32 , C07D405/10 , C07D217/24 , C07D417/14 , C07D417/12 , C07D413/12 , C07D405/12 , C07D403/12 , C07D403/10 , C07D401/12 , C07D401/10 , C07D491/048 , C07D487/04 , C07D471/04 , C07D417/10 , C07D413/10 , C07D513/04
CPC classification number: C07D237/32 , C07D217/24 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D513/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US20140206686A1
公开(公告)日：2014-07-24
申请号：US14157564
申请日：2014-01-17
Applicant: Bristol-Myers Squibb Company
Inventor： Peter W. Glunz , Yan Zou , Mimi L. Quan
IPC: C07D237/32 , C07D401/10 , C07D401/12 , C07D513/04 , C07D403/12 , C07D417/12 , C07D405/12 , C07D417/14 , C07D403/10 , C07D413/12
CPC classification number: C07D237/32 , C07D217/24 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D513/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性的ROCK抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其治疗心血管，平滑肌，肿瘤学，神经病理学，自身免疫性，纤维化和/或炎症性疾病的方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.047 seconds)
